Lysobact Celebrates 40th Birthday

Organized by the Chamber of Pharmaceutical Masters of FBiH, Zenica hosted the VII Symposium of Pharmaceutical Masters, attended by 800 pharmaceutical masters from all over Bosnia and Herzegovina. The symposium was international in nature with speakers from Macedonia, Serbia, Kosovo, Montenegro, and other countries. The theme of the symposium was "Pharmacist Competencies" or, simply put, acquiring new knowledge and skills, so that pharmaceutical masters can meet the modern demands of colleagues positioned throughout the European community.

The oldest Bosnian pharmaceutical company, Bosnalijek, supported this event and celebrated the big jubilee, the 40th birthday of one of the company's best-selling products - Lysobact.

Patients, doctors, and pharmacists associate Lysobact with tradition, trust, quality, and safety. The safety, as well as the absence of contraindications for Lysobact, stems from the natural component lysozyme, also known as the "enzyme of the future," which is not contained in other oral antiseptics on our market.

- Lysozyme is the first active antibacterial substance discovered by Alexander Fleming, before penicillin, and huge hopes were placed in lysozyme because it was capable of killing bacterial cells. Bosnalijek recognized the potential of lysozyme and has been using it in its products for 40 years. As a well-known and prosperous company, they sought even more, and after 40 years of successful application, they wanted to re-examine the possibilities of lysozyme. Now we are starting to examine lysozyme not as a substance that acts on the bacterial cell wall, but how lysozyme acts on bacterial groups. In addition, we conducted another study that we will publish soon - stated acc. prof. dr. Mirsada Hukić at the VII Symposium.

Lysobact is a clinically proven effective and safe medicine, with which more than 50 million patients worldwide have been successfully treated to date. This oral antiseptic, unique in many ways, whose top quality has long been recognized in the global pharmaceutical market, has sold over 50 million packs of tablets (lozenges) to patients in BiH, the region, and beyond during its 40 years of existence, without a single reported side effect.

By monitoring new research and expanding indications for use, we currently have four different forms of Lysobact on the market, and for more information, visit the website www.lysobact.ba.